A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. [electronic resource]
Producer: 20090924Description: 1731-9 p. digitalISSN:- 1549-4713
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Choroidal Neovascularization -- drug therapy
- Female
- Follow-Up Studies
- Humans
- Injections
- Macular Degeneration -- complications
- Male
- Middle Aged
- Ranibizumab
- Retreatment
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- drug effects
- Vitreous Body
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.